首页 › 弥漫性大B细胞淋巴瘤 › 加利福尼亚州 › Baldwin Park
Baldwin Park CA 弥漫性大B细胞淋巴瘤临床试验
19项针对 弥漫性大B细胞淋巴瘤的研究正在 Baldwin Park及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
招募中2 期
- City of Hope Comprehensive Cancer Center ( Site 0191), Duarte · 距离 4 英里
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
招募中1 期
- City of Hope Comprehensive Cancer Center, Duarte · 距离 4 英里
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
招募中1 期
- City of Hope, Duarte · 距离 4 英里
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
招募中1 期
- City of Hope, Duarte · 距离 4 英里
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
招募中2 期
- City of Hope, Duarte · 距离 4 英里
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
招募中2 期
- City of Hope Comprehensive Cancer Center, Duarte · 距离 4 英里
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
招募中1 期
- City of Hope Comprehensive Cancer Center, Duarte · 距离 4 英里
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
招募中1/2 期
- City of Hope, Duarte · 距离 4 英里
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
招募中1 期
- City of Hope Medical Center, Duarte · 距离 4 英里
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
招募中2 期
- City of Hope Medical Center, Duarte · 距离 4 英里
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
招募中2 期
- City of Hope Medical Center, Duarte · 距离 4 英里
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
招募中1 期
- City of Hope Comprehensive Cancer Center, Duarte · 距离 4 英里
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- City of Hope, Duarte · 距离 4 英里
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
招募中1 期
- City of Hope Medical Center, Duarte · 距离 4 英里
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
招募中1/2 期
- City of Hope, Duarte · 距离 4 英里
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- City of Hope, Duarte · 距离 4 英里
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
招募中2 期
- City of Hope Medical Center, Duarte · 距离 4 英里
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
招募中1 期
- City of Hope Medical Center, Duarte · 距离 4 英里
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
招募中早期 I 期
- City of Hope Medical Center, Duarte · 距离 4 英里
其他城市的 弥漫性大B细胞淋巴瘤试验
- New York City, NY20 项研究
- Los Angeles, CA18 项研究
- Houston, TX18 项研究
- Chicago, IL18 项研究
- Milwaukee, WI17 项研究
- Nashville, TN17 项研究
- Boston, MA17 项研究
- Philadelphia, PA15 项研究
- Durham, NC15 项研究
- Portland, OR15 项研究
- Cleveland, OH13 项研究
- Seattle, WA13 项研究
Baldwin Park的其他研究
- 乳腺癌43 项研究
- 急性髓系白血病41 项研究
- 结直肠癌37 项研究
- 非小细胞肺癌36 项研究
- 癌症（所有类型）34 项研究
- 前列腺癌31 项研究
- 转移性癌症30 项研究
- 卵巢癌27 项研究
- 骨髓增生异常综合征27 项研究
- 肺癌23 项研究
- 多发性骨髓瘤23 项研究
- 淋巴瘤22 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。